Tempus AI, Inc. (NASDAQ:TEM) Director Sells $46,361.70 in Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David R. Epstein sold 990 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $46.83, for a total value of $46,361.70. Following the completion of the sale, the director now owns 26,284 shares in the company, valued at $1,230,879.72. This represents a 3.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Tempus AI Stock Performance

Shares of NASDAQ:TEM opened at $51.35 on Friday. Tempus AI, Inc. has a 1 year low of $22.89 and a 1 year high of $91.45. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. The business’s 50 day simple moving average is $56.35 and its 200 day simple moving average is $51.40.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on TEM shares. Guggenheim restated a “buy” rating on shares of Tempus AI in a research note on Tuesday, February 25th. William Blair restated a “market perform” rating on shares of Tempus AI in a research note on Tuesday, February 25th. Morgan Stanley upped their target price on Tempus AI from $50.00 to $60.00 and gave the company an “overweight” rating in a research report on Thursday, March 6th. Loop Capital decreased their target price on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. Finally, TD Cowen reaffirmed a “buy” rating and issued a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Tempus AI has an average rating of “Moderate Buy” and an average target price of $61.18.

Institutional Investors Weigh In On Tempus AI

A number of large investors have recently added to or reduced their stakes in TEM. Operose Advisors LLC acquired a new stake in Tempus AI during the fourth quarter worth approximately $25,000. First Horizon Advisors Inc. acquired a new stake in shares of Tempus AI in the 3rd quarter valued at $30,000. Farther Finance Advisors LLC acquired a new stake in shares of Tempus AI in the 4th quarter valued at $34,000. Prestige Wealth Management Group LLC boosted its holdings in shares of Tempus AI by 910.4% in the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after purchasing an additional 965 shares in the last quarter. Finally, NewEdge Advisors LLC acquired a new stake in shares of Tempus AI in the 4th quarter valued at $49,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.